Last mentioned: Feb 27, 2026
TGA Approval
Australian regulators approve the Virtual Nodule Clinic for clinical use.
TGA Approval
Australian regulatory body approves the platform for clinical use in Australia.
CE Mark
Virtual Nodule Clinic receives CE marking for expansion into European markets.
Series A Funding
Company raises $14M to scale global commercial operations.
Series A Funding
Company raises $14M to scale its AI platform globally.
FDA Clearance
Optellum receives first-of-its-kind FDA clearance for lung cancer AI.
FDA Clearance
Optellum receives first-of-its-kind FDA clearance for AI lung cancer decision support.
Optellum has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) for its AI-powered Virtual Nodule Clinic. This milestone allows the company to deploy its lung cancer early-detection technology across the Australian healthcare system, marking a major expansion into the Asia-Pacific market.
Optellum has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. This expansion allows Australian clinicians to utilize advanced imaging analytics to improve early lung cancer detection and streamline patient care pathways.